Skip to content

Xiaoming Xu

Department of Medicine, Columbia University Irving Medical Center, New York, New York; Organic Chemistry Collaborative Center, Department of Medicine, Columbia University Irving Medical Center, New York, New York.

2 papers in the library · 8 citations · publishing 2025

Papers

Prophylactic (R,S)-Ketamine and (2S,6S)-Hydroxynorketamine Decrease Fear Expression by Differentially Modulating Fear Neural Ensembles.

Biological psychiatry May 1, 2025 Alessia Mastrodonato, Michelle Jin, Noelle Kee et al. 5 citations

A single injection of (R,S)-ketamine or its metabolite (2S,6S)-hydroxynorketamine (HNK) given one week before stress attenuated learned fear in male mice. The drugs altered neural activity in distinct and overlapping brain regions: (2S,6S)-HNK affected dorsal CA3, while both drugs changed activity in ventral CA3, CA1, infralimbic and prelimbic cortex, insular cortex, retrosplenial cortex, piriform cortex, nucleus reuniens, and periaqueductal gray. (R,S)-ketamine uniquely affected the paraventricular nucleus of the thalamus. (R,S)-ketamine increased connectivity between cortical and subcortical regions, whereas (2S,6S)-HNK increased connectivity within those regions. The findings identify novel fear network nodes that could be targeted to treat fear-induced disorders.

Effects of Binaural Beat Music and Esketamine for ECT in the Treatment of Major Depressive Disorder: A Randomized Controlled Trial Protocol.

Neuropsychiatric disease and treatment January 1, 2025 Ying Zhang, Zhaojuan Ke, Jie Luo et al. 3 citations

Major depressive disorder (MDD) is common and carries a high suicide risk. Electroconvulsive therapy (ECT) is highly effective but limited by adverse effects; ketamine/esketamine can boost ECT's efficacy and safety but have their own side effects. Binaural beat music (BBM), a non-invasive therapy, may improve mood and assist (es)ketamine. This 2×2 factorial, randomized, blinded clinical trial recruits 476 MDD patients requiring ECT, randomly assigned to four groups: blank sound with saline, blank sound with esketamine, BBM with saline, or BBM with esketamine. The primary outcome is response rate measured by the Hamilton depression scale; secondary outcomes include remission, suicidal ideation, cognitive function, and side effects. The data are expected to show BBM's potential for optimizing ECT strategies and improving patient outcomes.